Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CGEMBullishIndustry Newsnews

High materiality9/10

Phase 3 REZILIENT3 results bolster zipalertinib's ex20ins NSCLC prospects

Sep 13, 2026, 7:17 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Phase 3 PFS improvement, higher ORR, and OS trend could lift CGEM value; interim nature and safety signals demand caution.

AI summary

What happened, with direct paths to the underlying reporting

Phase 3 REZILIENT3 shows zipalertinib plus chemotherapy significantly improving first-line PFS in EGFR exon 20 insertion NSCLC, with median PFS 14.5 vs 8.5 months and higher response rates. Interim OS also trends favorably (HR 0.72 at 30% maturity). Data presented at WCLC 2026, Presidential Symposium, could support regulatory dialogue and drive near-term upside for CGEM's ex20ins program.

REZILIENT3: zipalertinib + chemo cut interim PFS to 14.5 vs 8.5 months.
HR 0.50 (P=0.00015) at 122 events; OS HR 0.72 at 30% maturity.
ORR 65.0% vs 40.3%; DoR longer (14.2 vs 9.9 months).
Brain mets subgroup HR 0.38; results presented at WCLC Presidential Symposium.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Phase 3 REZILIENT3 results bolster zipalertinib's ex20ins NSCLC prospects

REZILIENT3 topline PFS success boosts zipalertinib program

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations